SBC Medical Group Holdings (SBC) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
26 Aug, 2026Executive summary
Q2 2026 revenue rose 13–13.4% year-over-year to $49–$49.2 million, with net income attributable to shareholders up 335% to $10.7–$11 million, driven by AI-enabled service enhancements, higher management services revenue, and network expansion.
Adjusted EBITDA increased 32% year-over-year to $20 million, with margin expanding to 41%.
Strategic focus on multi-brand aesthetic dermatology, non-aesthetic healthcare as a second growth engine, global expansion (notably in the U.S. and Southeast Asia), and AI-driven cost structure reform.
Completed structural reforms in 2025, entering a phase of re-accelerated growth with profit growth outpacing revenue growth.
Expanded business base and enhanced support functions, notably through AI, driving operational efficiency and customer experience.
Financial highlights
Q2 2026 total revenues: $49–$49.2 million (+13–13.4% YoY); net income: $10.7–$11 million (+335% YoY); adjusted EBITDA: $20 million (+32% YoY); adjusted EBITDA margin: 41%.
Net income margin for Q2 2026: 21.7–22% (+16pt YoY); basic EPS: $0.10 (+400% YoY).
Gross profit for Q2 2026: $36 million (+19.9% YoY); gross margin: 73.1%.
Cash and cash equivalents as of June 30, 2026: $184–$184.3 million; capital ratio: 64.9%.
Year-to-date clinic revenue rose 11%, same clinic revenue up 6%, and average spend per visit increased 9% to $287.
Outlook and guidance
AI-enabled platform and revised service agreements expected to drive sustainable growth in clinic locations, average fee per clinic, and service breadth, with $15 million in annualized management service revenue increases anticipated.
Continued strong growth in customer volume and unit price expected, with further improvements anticipated in Q3 and Q4.
Targeting 1,000 clinics by 2035, with a shift toward greater non-aesthetic healthcare revenue and entry into the Longevity market.
U.S. and Southeast Asia strategies focus on asset-light expansion and leveraging local partnerships.
Latest events from SBC Medical Group Holdings
- AI-driven growth, global expansion, and multi-brand strategies fuel accelerating performance.SBC
Small-Cap Virtual Conference - Profit and revenue surged as AI, new formats, and global expansion fueled renewed growth.SBC
Q3 Investor Summit Group Virtual Conference 2026 - Q2 2026 saw accelerated growth, AI-driven efficiency, and expansion in healthcare and global markets.SBC
Emerging Growth Conference - Leading Japanese aesthetic clinic group achieves rapid global growth and strong financial results.SBC
Corporate presentation - All director nominees and charter amendments were approved at the virtual annual meeting.SBC
AGM 2026 - Underlying growth, AI-driven efficiency, and longevity-focused expansion drive future prospects.SBC
Sidoti Small-Cap Virtual Investor Conference - AI-driven, multi-brand healthcare model targets global expansion and double-digit growth.SBC
Emerging Growth Conference 93 - Largest aesthetic clinic network in Japan, expanding globally with high growth and profitability.SBC
Investor presentation - Strong financials, global expansion, and strategic initiatives drive growth and shareholder value.SBC
Life Sciences Investor Forum